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Metabolic and bioenergetic dysfunction are associated with oxidative stress and thought to be a common
underlying mechanism of chronic diseases such as atherosclerosis, diabetes, and neurodegeneration.
Recent ﬁndings support an emerging concept that circulating leukocytes and platelets can act as sensors
or biomarkers of mitochondrial function in patients subjected to metabolic diseases. It is proposed that
systemic stress-induced alterations in leukocyte bioenergetics are the consequence of several factors
including reactive oxygen species. This suggests that oxidative stress mediated changes in leukocyte
mitochondrial function could be used as an indicator of bioenergetic health in individuals. To test this
concept, we investigated the effect of the redox cycling agent, 2,3 dimethoxynaphthoquinone (DMNQ) on
the bioenergetic proﬁles of monocytes isolated from healthy human subjects using the extracellular ﬂux
analyzer. In addition, we tested the hypothesis that the bioenergetic health index (BHI), a single value
that represents the bioenergetic health of individuals, is dynamically sensitive to oxidative stress in
human monocytes. DMNQ decreased monocyte ATP-linked respiration, maximal respiration, and reserve
capacity and caused an increase in proton leak and non-mitochondrial respiration compared to mono-
cytes not treated with DMNQ. The BHI was a more sensitive indicator of the DMNQ-dependent changes
in bioenergetics than any individual parameter. These data suggest that monocytes are susceptible to
oxidative stress mediated by DMNQ and this can be accurately assessed by the BHI. Taken together, our
ﬁndings suggest that the BHI has the potential to act as a functional biomarker of the impact of systemic
oxidative stress in patients with metabolic disorders.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mitochondria are both a source and target for oxidative stress
and the failure to maintain mitochondrial quality by the appro-
priate balance of biogenesis and autophagy ultimately leads to cell
death [1–4]. Many of the chronic diseases which afﬂict aging po-
pulations, such as diabetes and atherosclerosis, are associated with
both increased systemic oxidative stress and mitochondrial dys-
function [1,3,5,6]. Translation of these ideas to the clinic in dis-
eases such as diabetes and cardiac surgery has resulted in the
hypothesis that circulating platelets or monocytes can serve asB.V. This is an open access article u
health index; DMNQ, 2,3 di-
hloride; FCCP, carbonyl cya-
racellular ﬂux; OCR, oxygen
iversity of Alabama at Bir-
treet South, Birmingham, ALbioenergetic biomarkers of the systemic exposure to metabolic
stressors or pro-inﬂammatory cytokines [7–11]. Indeed, a broad
range of environmental, dietary and epidemiological studies have
shown distinct patterns of cytokine proﬁles in patients with
chronic inﬂammatory diseases such as cancer, diabetes, obesity,
and metabolic syndrome [12–15]. Another study reported that
human mononuclear cells isolated from Type 2 diabetic patients
have alterations in mitochondrial morphology, mitochondrial
mass and membrane potential [16]. These data highlight how
measurement of cellular bioenergetics in leukocytes and platelets
can act as a surrogate index of mitochondrial function in several
pathologies including Alzheimer's disease or in some cases can be
directly related to underlying pathologies such as autoimmune
diseases [17–19]. Since mitochondria are particularly susceptible
to oxidative stress, we hypothesized that the bioenergetics in cir-
culating monocytes would exhibit a dose dependent change in
response to oxidants.
We have recently developed methods to assess the changing
dynamics of bioenergetic function in leukocytes and platelets from
human subjects [20–22]. Importantly, we have determined thatnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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distinct in platelets, monocytes, neutrophils and lymphocytes
which suggests that their response to oxidative stress will also
differ [23]. Mitochondrial cellular function can be deﬁned using a
stress test in which the addition of oxidative phosphorylation in-
hibitors can cause alterations in a cell's oxygen consumption rate
(OCR) and bioenergetic proﬁle [24,25]. The mitochondrial para-
meters from the stress test include ATP linked respiration, proton
leak, maximal respiration, the reserve capacity and non-mi-
tochondrial respiration [1]. Each of these parameters are all un-
iquely sensitive to different free radicals or oxidants. The inter-
active nature of these parameters has led us to propose that an
integrated single value known as the Bioenergetic Health Index
(BHI) can be used as a measurement of changing bioenergetic
health in human subjects for translational medicine [21]. Speciﬁ-
cally, this integrated value could be useful for prognostic or diag-
nostic value. We have previously shown that the BHI is sig-
niﬁcantly depressed in monocytes isolated from the post-opera-
tive pericardial ﬂuid of patients undergoing cardiac surgery [26]
and this is associated with the highly oxidative environment of the
pericardial ﬂuid following surgery [11].
In the present study, we tested whether the response of
monocytes isolated from healthy human subjects show a differ-
ential response to oxidative stress produced by 2, 3 dimethox-
ynapthoquinone (DMNQ). DMNQ is a redox cycling agent that
generates both superoxide and hydrogen peroxide intracellularly
in a concentration dependent manner [27]. These two oxidants are
known to be generated in a broad range of pathological conditions
associated with inﬂammation due to the activation of the NADPH
oxidases [28–30]. The concept that cells isolated from patients
may exhibit increased susceptibility to the oxidants generated by
DMNQ has recently been tested in subjects with autistic disorder
[31]. Speciﬁcally, it was determined that lymphoblastoid cells from
a subgroup of children with autistic disorder had increased mi-
tochondrial dysfunction due to DMNQ mediated oxidative stress
compared to another subgroup of children with autistic disorder.
In the present study, we examined the impact of varying con-
centrations of DMNQ in monocytes isolated from healthy subjects.
Additionally, we evaluated the utility of the BHI to detect mi-
tochondrial dysfunction induced by DMNQ in monocytes. Inter-
estingly, the BHI was suppressed with increasing DMNQ con-
centrations and was found to be a more sensitive parameter than
individual parameters derived from the mitochondrial stress test.
Our ﬁndings suggest that the BHI is dynamically sensitive to acute
oxidative stress in human monocytes and could be a potential
functional biomarker of oxidative stress in patients suffering from
metabolic disorders.2. Materials and methods
2.1. Materials
DMNQ (2,3 dimethoxynapthoquinone) was purchased from
Enzo Life Sciences (Farmingdale, NY, USA). RPMI was obtained
from Life Technologies (Grand Island, NY, USA). Materials for the
extracellular ﬂux assays were from Seahorse Biosciences (North
Billerica, MA, USA). BSA, Oligomycin, FCCP (carbonyl cyanide 4-
(triﬂuoromethoxy) phenylhydrazone), Antimycin A and dipheny-
leneiodonium chloride (DPI) were all purchased from Sigma-Al-
drich (St. Louis, MO, USA).
2.2. Human subjects
The work described here has been carried out in accordance
with the Declaration of Helsinki. All study protocols for thecollection and handling of human samples were reviewed and
approved by the Institutional Review Board at the University of
Alabama at Birmingham. Written informed consent was obtained
from all participants. Blood samples (24 ml) were collected from
healthy control subjects (no medications or known pathological
conditions, n¼4–11, 3 males, 8 females, age 30.773.6 years) in
vacutainers (BD Biosciences, Franklin Lakes, NJ, USA) containing
1.5 ml ACD solution.
2.3. Monocyte isolation from blood
All samples were processed as described previously [20,22]. In
brief, the platelet-rich plasma and buffy coat were separated by
centrifugation at 500 g for 10 min. The buffy coat was diluted with
RPMI media before being applied to a histopaque density gradient
to collect peripheral blood mononuclear cells. Afterwards, anti-
body bead selection and a series of centrifugations were im-
plemented to collect CD14þ monocytes before determining cell
counts using the Bio-Rad TC20 automated cell counter (Bio-Rad
Laboratories, Hercules, CA, USA). The typical yield of cells from
24 ml of blood was 5.771.0106 cells.
2.4. Cellular bioenergetics analysis and the Bioenergetic Health Index
(BHI)
The Seahorse Biosciences XF96 extracellular ﬂux analyzer was
used to determine the effects of the oxidative stressor, DMNQ, on
cellular bioenergetics in human monocytes. Puriﬁed monocytes
(150,000 cells/well) were resuspended in XF assay buffer (DMEM
with 1 mM pyruvate, 5.5 mM D-glucose, 4 mM L-glutamine, pH 7.4)
and plated in Cell-Tak (BD Biosciences, Franklin Lakes, NJ, USA)
coated assay plates as we have recently described [22]. Cells were
pretreated with DMNQ (0.05, 0.1, 0.2, 1 and 5 mM) for 1 h at 37 °C
before measuring the oxygen consumption rate (OCR). Dimethyl
sulfoxide (DMSO) was used as a vehicle control. The mitochondrial
stress test was performed by injecting oligomycin (0.5 mg/mL), FCCP
(0.6 mM), and antimycin A (10 mM) sequentially into the cellular
media. From this assay we calculated the following parameters: ATP-
linked respiration, proton leak respiration, maximal OCR, reserve
capacity, and non-mitochondrial respiration [1,25]. The Bioenergetic
Health Index (BHI) was calculated using the following formula: BHI¼
(ATP-linked reserve capacity)/(proton leaknon-mitochondrial)
[21]. In additional experiments, monocytes were treated with DPI (1,
5, and 10 mM) for 15 min prior to being treated with 0.2 mM DMNQ
for 1 h and performing the mitochondrial stress test.
2.5. Statistical analysis
The statistical analysis was performed using GraphPad Prism
software (La Jolla, CA, USA). Data is presented as mean7standard
error of the mean (SEM). Individual measurements were com-
prised of 5–6 technical replicates and analyzed as a group by
taking the mean of the bioenergetic parameters for each in-
dividual. A p value less than 0.05 was considered statistically sig-
niﬁcant. The statistical signiﬁcance was determined using a two-
tailed paired Student's t-test or ANOVA with Tukey post-hoc test
for data with more than two groups as appropriate.3. Results
3.1. DMNQ alters cellular bioenergetics in monocytes from healthy
subjects
To investigate the sensitivity of monocyte mitochondrial func-
tion to acute oxidative stress, we utilized the redox cycling agent,
Fig. 1. The effect of DMNQ on monocyte mitochondrial function. Monocytes from healthy subjects were seeded (150,000 cells/well) on Cell-Tak coated Seahorse XF 96-well
plates. Cells were pretreated with DMNQ (0.05, 0.1, 0.2, 1 and 5 mM) or vehicle control (DMSO) for 1 h prior to measuring the basal respiration and OCR following oligomycin
(Oligo), FCCP, and antimycin A (AA) injections. (A) Representative OCR traces in monocytes from one individual treated with vehicle or 0.05 and 0.2 mM DMNQ. Results are
mean7SEM, n¼5–6 technical replicates per group. The effect of DMNQ on (B) basal; (C) ATP-Linked; (D) proton leak; (E) maximal; (F) reserve capacity; and (G) non-
mitochondrial OCR from n¼4–8 healthy subjects. Results are mean7SEM, *po0.05 compared to controls not treated with DMNQ.
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Fig. 2. The effect of DMNQ on monocyte BHI. Healthy subject monocytes were
seeded (150,000 cells/well) on Cell-Tak coated Seahorse XF 96-well plates and
pretreated with DMNQ (0.05, 0.1, 0.2, 1 and 5 mM) or vehicle control for 1 h prior to
measuring mitochondrial function. (A) The effect of increasing DMNQ concentra-
tions on the BHI of monocytes from n¼4–8 healthy subjects. (B) Percent change in
BHI, proton leak, maximal, reserve capacity, and non-mitochondrial OCR in DMNQ
treated cells (0.1 and 0.2 mM) compared to controls. (C) The effect of DPI, a NADPH
oxidase inhibitor (10 mM), on non-mitochondrial respiration in monocytes treated
with 0.2 mM DMNQ. Results are mean7SEM from 2–3 healthy subjects, *po0.05
compared to controls not treated with DMNQ and #po0.05 compared to cells
treated with 0.2 mM DMNQ.
B.K. Chacko et al. / Redox Biology 8 (2016) 43–5046DMNQ. In these series of experiments, monocytes from healthy
subjects were pre-treated with varying concentrations of DMNQ
(0.05, 0.1, 0.2, 1 and 5 mM) or vehicle control for 1 h before as-
sessing cellular bioenergetics using the mitochondrial stress test.
Fig. 1A illustrates a representative proﬁle of monocytes from a
single individual treated with DMNQ (0.05 and 0.2 mM) or vehicle
control for 1 h. DMNQ had no effect on basal OCR over the ﬁrst
20 min of the assay. Next, the complex V inhibitor, oligomycin, was
injected onto the cells and caused a rapid decline in the OCR in
both control and DMNQ treated groups (0.05 and 0.2 mM) (Fig. 1A).
The remaining respiration or proton leak was similar between
controls and monocytes treated with 0.05 mM DMNQ. However,
0.2 mM DMNQ increased proton leak. To assess maximal respira-
tion, FCCP was injected after 40 min. FCCP stimulated maximal
respiration in both controls and monocytes treated with 0.05 mM
DMNQ. In contrast, cells treated with 0.2 mM DMNQ had decreased
FCCP stimulated maximal respiration compared to control cells.
Lastly, antimycin A was injected onto the cells after 60 min to
measure non-mitochondrial respiration. Antimycin A signiﬁcantly
decreased OCR to the same extent in all groups (Fig. 1A).
The effect of DMNQ (0.05, 0.1, 0.2, 1 and 5 mM) on each bioe-
nergetic parameter was determined using the bioenergetic proﬁle
from a number of healthy subjects and plotted as a function of
DMNQ concentration (Fig. 1B–G). Basal respiration was calculated
by subtracting the initial OCR from the OCR following Antimycin A
injection. Increasing DMNQ concentrations had no effect on basal
respiration (Fig. 1B). Next, ATP-linked respiration was determined
by subtracting oligomycin stimulated OCR from the basal OCR. The
highest DMNQ concentration (5 mM) caused a signiﬁcant decline in
ATP-linked respiration compared to controls. Interestingly, lower
doses of DMNQ had no effect on proton leak compared to controls;
whereas, 1 and 5 mM DMNQ increased proton leak signiﬁcantly
compared to control monocytes (Fig. 1D). Maximal respiration was
determined after the addition of the mitochondrial uncoupler
FCCP and was inhibited by DMNQ with an IC50 of 0.208 mM
(Fig. 1E). Exposure to higher concentrations of DMNQ (0.2, 1, and
5 mM) inhibited maximal respiration (Fig. 1E). As a result, DMNQ
signiﬁcantly decreased the reserve capacity in 0.2, 1 and 5 mM
DMNQ treated groups (Fig. 1F). The reserve capacity was calculated
by subtracting basal from maximal OCR. Lastly, the non-mi-
tochondrial respiration was determined. As shown in Fig. 1G, non-
mitochondrial respiration increased signiﬁcantly with increasing
DMNQ concentrations. Out of all of the parameters, non-mi-
tochondrial respiration was the ﬁrst parameter to show a sig-
niﬁcant change at the lowest DMNQ concentration. This was ex-
pected due to the oxygen consumption associated with the gen-
eration of superoxide and hydrogen peroxide mediated by DMNQ
[32].
3.2. DMNQ decreases the BHI in monocytes from healthy subjects
The effect of DMNQ on the BHI in healthy control subject
monocytes was established. As shown in Fig. 2A, increasing con-
centrations of DMNQ caused a signiﬁcant decline in the BHI. In
particular, 0.1–0.2 mM DMNQ decreased BHI signiﬁcantly com-
pared to monocytes not treated with DMNQ (4578.99 controls vs.
257 5.37 or 97 2.63 for 0.1 and 0.2 mM respectively). The BHI
was further depleted below zero with higher concentrations of
DMNQ (17 0.31 or 17 0.16 for 1 and 5 mM DMNQ respec-
tively). The effect of DMNQ on the BHI and certain bioenergetic
parameters in monocytes was calculated. OCR rates were com-
pared on a % basis to allow comparison of the DMNQ-dependent
changes in BHI, proton leak, maximal, reserve capacity, and non-
mitochondrial respiration. As shown in Fig. 2B, 0.1 and 0.2 mM
DMNQ caused a 55% and 80% decrease in the BHI respectively.
Importantly, these changes in BHI occurring at 0.1 mM DMNQ werenot associated with changes in proton leak, maximal, or reserve
capacity. However, it did cause a 30% increase in non-mitochon-
drial respiration in monocytes. In contrast, 0.2 mM DMNQ caused a
signiﬁcant increase in proton leak and a decrease in both maximal
and reserve capacity (25% and 50% respectively) compared to
Fig. 3. The sensitivity of the BHI and individual mitochondrial parameters to DMNQ. Healthy subject monocytes were seeded (150,000 cells/well) on Cell-Tak coated
Seahorse XF 96-well plates and pretreated with DMNQ (0.05, 0.1, and 0.2 mM) or vehicle control for 1 h prior to measuring mitochondrial function. (A) The BHI of individual
healthy subject monocytes before and after 0.05 or 0.1 mM DMNQ treatment. (B) The sensitivity of each mitochondrial parameter to 0.2 mM DMNQ treatment in monocytes
was determined. Results are mean7SEM, n¼5–6 technical replicates per group, *po0.05 compared to controls not treated with DMNQ. n¼4–8 healthy subjects.
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did not further increase non-mitochondrial respiration. To evalu-
ate whether NADPH oxidases may be responsible for increased
non-mitochondrial respiration, cells were treated with DPI, an
NAPDH oxidase inhibitor. As shown in Fig. 2C, pretreating the cells
with increasing concentrations of DPI (1, 5, and 10 mM) caused a
signiﬁcant decrease in DMNQ mediated non-mitochondrial re-
spiration. These data suggest that the BHI and individual para-
meters are dynamically sensitive to oxidative stress mediated by
DMNQ.
3.3. The BHI is more sensitive to DMNQ than individual mitochon-
drial parameters
To test the possibility that different healthy subjects may ex-
hibit differential DMNQ-dependent sensitivity to BHI and mi-
tochondrial parameters, a more detailed analysis was performed
based on individual proﬁles. As shown in Fig. 3A and B, the lowest
DMNQ (0.05 mM, 0.1 mM) concentrations signiﬁcantly decreased
the BHI in three of the four healthy subjects while one subject was
more resistant (Fig. 3A and B). The sensitivity of each mitochon-
drial parameter to 0.2 mM DMNQ treatment in monocytes from
eight individuals was next determined. Both basal and ATP-linked
respiration showed only minor variation with DMNQ treatment
amongst individuals (Fig. 3C and D). However, proton leak was
signiﬁcantly increased to approximately the same extent in seven
of the eight participants (Fig. 3E). Both the maximal respiration
and reserve capacity was signiﬁcantly decreased with 0.2 mM
DMNQ treatment in 7 of the 8 subjects (Fig. 3F and G). Lastly,
DMNQ signiﬁcantly elevated non-mitochondrial respiration to the
same extent in 7 of the 8 subjects suggesting that the extent of
redox cycling does not change signiﬁcantly between individuals
but should be independently assessed (Fig. 3H).4. Discussion
Mitochondrial function has been shown to be impaired in
leukocytes and platelets in systemic pathologies such as sepsis and
ﬁbromyalgia [33,34]. The mechanisms responsible for these im-
pairments are thought to be inﬂuenced by reactive oxygen species
(ROS). Understanding these mechanisms further could be useful to
develop diagnostic or prognostic assays to clinically beneﬁt pa-
tients with systemic diseases. The purpose of this study was to
determine whether acute oxidative stress generated by the redox
cycling agent, DMNQ, alters cellular bioenergetics in monocytes
from healthy subjects. In addition, we tested whether these mi-
tochondrial changes could be detected by the BHI, a single value
that represents mitochondrial function in cells. We have pre-
viously determined that DMNQ alters cellular bioenergetics in
neuronal and endothelial cells [32,35], and more recently in lym-
phocytes [36]. We opted to focus on monocytes in the current
study because they are vital to the innate immune system and play
an important role in the resolution of inﬂammation caused by
tissue injury or infection [37]. They also rely on mitochondrial
metabolism to carry out cellular processes such as differentiation
and phagocytosis to mitigate inﬂammation. Lastly, they are in-
volved in the pathogenesis of a number of systemic diseases such
as atherosclerosis, stroke, and rheumatoid arthritis [38].
We determined that DMNQ lowered monocyte cellular bioe-
nergetics in a concentration dependent manner compared to
control cells not treated with DMNQ. In particular, DMNQ lowered
ATP-linked respiration, maximal respiration, and depleted reserve
capacity. Monocytes treated with higher DMNQ concentrations (1
and 5 mM) had a reserve capacity below zero and this suggests that
DMNQ diminished the monocyte's ability to respond to cellularbioenergetic demand. The current data suggests that DMNQ could
be causing poor mitochondrial respiratory complex integrity or
substrate availability in these cells. It is clear that DMNQ also
caused increased ROS generation as evidenced by the elevation in
non-mitochondrial respiration at all concentrations. This alone can
affect respiratory complex integrity or substrate availability. As
expected, non-mitochondrial ROS increases with DMNQ con-
centration and this is inhibited by DPI. This is consistent with a
role of ﬂavoproteins in promoting redox cycling by DMNQ [27].
Importantly, we identiﬁed for the ﬁrst time that the BHI is
dynamically sensitive to oxidative stress mediated by DMNQ in
monocytes from healthy human subjects. The individual subjects
tested in this study showed highly signiﬁcant changes in BHI when
analyzed as a group and similar responses to DMNQ for speciﬁc
parameters although analysis of individual responses suggest that
signiﬁcant personal differences could emerge in studies with lar-
ger populations. This study was not designed to determine whe-
ther differential responses to BHI are associated with age, gender
or ethnicity. To determine the association of BHI to these demo-
graphic factors, samples with wider representation will be in-
vestigated in future studies.
The ﬁndings from these studies support the concept that the
BHI can be used to monitor the extent of disease in individuals
affected by pathologies inﬂuenced by oxidative stress such as
atherosclerosis, diabetes, and neurodegeneration. We determined
that concentrations as low as 0.1 mM DMNQ decreases BHI in
monocytes and progressively decreased with increasing DMNQ
concentrations. The BHI is an integrated measure of mitochondrial
function and as such should be more sensitive than any of the
individual parameters that can be derived from the mitochondrial
stress test. The parameters that comprise the BHI include proton
leak, reserve capacity, ATP linked respiration and what we have
termed non-mitochondrial respiration [21]. The inclusion of non-
mitochondrial respiration in the calculation of the BHI is based
upon the established literature which shows mitochondria are
both a source and target for the effects of ROS and RNS [39]. Ex-
perimentally, this parameter is deﬁned as the value for OCR which
remains after antimycin inhibition and may differ between cell
types. Potential contributors include the cytochrome P450s, cy-
clooxygenases, NADPH oxidases and possibly intra-mitochondrial
sources of ROS. We found that in monocytes, a substantial pro-
portion of the non-mitochondrial OCR is sensitive to low con-
centrations of DPI suggesting that a ﬂavoprotein is a major con-
tributor. Clearly, this is an area warranting further investigation.
In the current protocol, the redox cycling of DMNQ is making a
signiﬁcant contribution as we have shown previously in en-
dothelial cells [32,40]. Importantly, we found that although both
maximal respiration and reserve capacity showed signiﬁcant de-
creases to 0.2 mM DMNQ, the BHI exhibited a signiﬁcant decrease
at 0.1 mM. To take into account whether non-mitochondrial re-
spiration was primarily responsible for the decline observed in
BHI, we evaluated the signiﬁcance of each parameter on the BHI.
We noted that at lower DMNQ concentrations (0.05 mM), proton
leak, reserve capacity, or non-mitochondrial respiration was re-
sponsible for the decline in BHI in certain individuals (data not
shown). However, non-mitochondrial respiration appeared to be a
major factor for decreased BHI at higher DMNQ concentrations (0.1
and 0.2 mM) (data not shown). This is important to note because in
pathologies where ROS are involved, either of the parameters
could drive a decline in BHI based on the severity of oxidative
stress. Moreover, it appears that the BHI detected these responses
more accurately than any individual parameter alone. These
ﬁndings highlight the potential of the BHI to be a sensitive pre-
dictor of mitochondrial dysfunction in patients.
In conclusion, these data illustrate that DMNQ negatively af-
fects cellular bioenergetics in monocytes and that the BHI is highly
B.K. Chacko et al. / Redox Biology 8 (2016) 43–50 49sensitive to this stressor. The inﬂuence of DMNQ on the BHI in
human monocytes could model the response observed in patients
with pathologies where oxidative stress is exacerbated. We de-
veloped the BHI to assess the bioenergetic health of cells and to
use this information to potentially monitor an individual's disease
progression or response to treatment. The data presented here
supports the emerging recognition of the important link between
mitochondria and oxidative stress in monocytes in human sub-
jects. In this study, DMNQ has been used as a prototypical example
of a redox cycling compound to expose cells to controlled levels of
intracellular ROS. It is important to note that many therapeutics,
particularly anti-cancer agents, promote oxidative stress and in
some cases this may contribute to unwanted side effects. The
techniques we describe here could be applied to precision medi-
cine by determining the susceptibility of patients to the pro-oxi-
dant effects of therapeutics prior to administration and monitoring
bioenergetic health during treatment. It is likely that this approach
could also be extended to other cell types that can be isolated from
human blood. For example, it has been shown that platelets from
sickle cell disease, a known condition in which oxidative stress is
increased, show a profound decrease in the key parameters of the
mitochondrial stress test [41]. A further application of this ap-
proach has been reported in cells isolated from patients with au-
tistic disorder in which DMNQ was used as a stressor ex-vivo [31].
This experimental paradigm potentially makes it possible to pre-
dict the susceptibility of a condition associated with oxidative
stress. Future studies will determine whether cellular bioener-
getics and the BHI are altered in patients affected by systemic
disorders and whether these parameters could be a potential
biomarker to monitor disease progression or susceptibility in
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